JP2018507252A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018507252A5 JP2018507252A5 JP2017558359A JP2017558359A JP2018507252A5 JP 2018507252 A5 JP2018507252 A5 JP 2018507252A5 JP 2017558359 A JP2017558359 A JP 2017558359A JP 2017558359 A JP2017558359 A JP 2017558359A JP 2018507252 A5 JP2018507252 A5 JP 2018507252A5
- Authority
- JP
- Japan
- Prior art keywords
- suspension according
- suspension
- ophthalmic
- active ingredient
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000725 suspension Substances 0.000 claims 16
- 239000004480 active ingredient Substances 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229940100654 ophthalmic suspension Drugs 0.000 claims 4
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 229920002125 Sokalan® Polymers 0.000 claims 3
- 229920002678 cellulose Polymers 0.000 claims 3
- 239000001913 cellulose Substances 0.000 claims 3
- 229960004875 difluprednate Drugs 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 2
- 229920000148 Polycarbophil calcium Polymers 0.000 claims 2
- 229950009769 etabonate Drugs 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 229950005134 polycarbophil Drugs 0.000 claims 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 229960001631 carbomer Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 claims 1
- 229960003744 loteprednol etabonate Drugs 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920001992 poloxamer 407 Polymers 0.000 claims 1
- 229940044476 poloxamer 407 Drugs 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562107696P | 2015-01-26 | 2015-01-26 | |
| US62/107,696 | 2015-01-26 | ||
| PCT/US2016/014872 WO2016123079A1 (en) | 2015-01-26 | 2016-01-26 | Ophthalmic suspension composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018507252A JP2018507252A (ja) | 2018-03-15 |
| JP2018507252A5 true JP2018507252A5 (enExample) | 2019-03-07 |
Family
ID=55359733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017558359A Pending JP2018507252A (ja) | 2015-01-26 | 2016-01-26 | 眼用懸濁組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10596107B2 (enExample) |
| EP (5) | EP4268850B1 (enExample) |
| JP (1) | JP2018507252A (enExample) |
| KR (1) | KR102538370B1 (enExample) |
| CN (1) | CN107427464B (enExample) |
| AU (4) | AU2016211745A1 (enExample) |
| BR (1) | BR112017016016B1 (enExample) |
| CA (1) | CA2975106A1 (enExample) |
| ES (5) | ES2966595T3 (enExample) |
| HU (5) | HUE066045T2 (enExample) |
| MX (1) | MX390671B (enExample) |
| PL (5) | PL4082531T3 (enExample) |
| PT (3) | PT3721868T (enExample) |
| SI (1) | SI4268850T1 (enExample) |
| WO (1) | WO2016123079A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3721868T (pt) * | 2015-01-26 | 2022-08-12 | Bausch & Lomb | Composição para suspensão oftálmica |
| CA3001955C (en) | 2015-10-16 | 2023-11-28 | Sun Pharma Advanced Research Company Limited | Ophthalmic solution of difluprednate |
| LT3245988T (lt) | 2016-05-18 | 2024-02-12 | Sonikure Holdings Limited | Ultragarsu pagerinto transsklerinio vaistų pristatymo sistema |
| AU2018318123B2 (en) | 2017-08-15 | 2024-07-25 | Nephron Pharmaceuticals Corporation | Aqueous nebulization composition |
| CA3112278A1 (en) * | 2018-09-21 | 2020-03-26 | Ps Therapy Ltd. | Artificial tear, contact lens and drug vehicle compositions and methods of use thereof |
| JP6994061B2 (ja) * | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| US20220162170A1 (en) * | 2019-02-15 | 2022-05-26 | Novartis Ag | Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof |
| JP2023505409A (ja) * | 2019-08-18 | 2023-02-09 | アイビュー セラピューティクス（ズーハイ）カンパニー リミテッド | 持続型の眼用薬物送達システムとしてシクロスポリンミセルを含むｉｎ－ｓｉｔｕゲル |
| KR102271247B1 (ko) * | 2020-11-04 | 2021-06-30 | 삼천당제약주식회사 | 안과용 현탁액 조성물의 제조방법 |
| CN115554238A (zh) * | 2022-10-25 | 2023-01-03 | 苏州欧康维视生物科技有限公司 | 眼用混悬液及其制备方法 |
| CN115887372A (zh) * | 2022-10-25 | 2023-04-04 | 苏州欧康维视生物科技有限公司 | 丙酸氟替卡松混悬液及其制备方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4996335A (en) | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
| US4540930A (en) | 1983-09-12 | 1985-09-10 | Wisconsin Alumni Research Foundation | Plywheel-powered mobile X-ray apparatus |
| WO1985002092A1 (en) | 1983-11-14 | 1985-05-23 | Bio-Mimetics Inc. | Bioadhesive compositions and methods of treatment therewith |
| NZ226171A (en) | 1987-09-18 | 1990-06-26 | Ethicon Inc | Gel formulation containing polypeptide growth factor |
| IE63392B1 (en) | 1988-02-08 | 1995-04-19 | Insite Vision Inc | Ophthalmic suspensions |
| US5192535A (en) | 1988-02-08 | 1993-03-09 | Insite Vision Incorporated | Ophthalmic suspensions |
| US5124154A (en) | 1990-06-12 | 1992-06-23 | Insite Vision Incorporated | Aminosteroids for ophthalmic use |
| US5252318A (en) | 1990-06-15 | 1993-10-12 | Allergan, Inc. | Reversible gelation compositions and methods of use |
| CA2134376C (en) | 1993-12-20 | 2001-10-23 | Haresh G. Bhagat | Combinations of polymers for use in physiological tear compositions |
| AU684115B2 (en) * | 1993-12-27 | 1997-12-04 | Mitsubishi Chemical Corporation | Ophthalmic suspension containing diflupredonate |
| GB9718568D0 (en) * | 1997-09-03 | 1997-11-05 | Chauvin Pharmaceuticals Limite | Compositions |
| TWI227143B (en) | 1999-12-15 | 2005-02-01 | Guo-Jiun Sung | In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method |
| AR033151A1 (es) * | 2001-04-12 | 2003-12-03 | Sucampo Pharmaceuticals Inc | Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares |
| US7001615B1 (en) | 2001-12-07 | 2006-02-21 | Alcon, Inc. | Sustained release ophthalmic, otic and nasal suspension |
| EP2283864A1 (en) * | 2002-07-16 | 2011-02-16 | Elan Pharma International Ltd. | Liquid dosage compositions fo stable nanoparticulate active agents |
| CN100475192C (zh) | 2003-06-13 | 2009-04-08 | 爱尔康公司 | 包含两种聚合物的协同组合的眼用组合物 |
| US20050197303A1 (en) | 2003-10-31 | 2005-09-08 | Bausch & Lomb Incorporated | Combination of loteprednol etabonate and tobramycin for topical ophthalmic use |
| US20050182039A1 (en) * | 2004-02-13 | 2005-08-18 | Bausch & Lomb Incorporated | Use of Loteprednol etabonate for the treatment of dry eye |
| TWI358290B (en) | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
| US7919483B2 (en) | 2005-06-24 | 2011-04-05 | Medicis Pharmaceutical Corporation | Method for the treatment of acne |
| US20120028947A1 (en) | 2005-11-14 | 2012-02-02 | Erning Xia | Ophthalmic Compositions |
| WO2007058935A2 (en) | 2005-11-14 | 2007-05-24 | Bausch & Lomb Incorporated | Ophthalmic composition for dry eye therapy |
| US20100234336A1 (en) | 2005-11-14 | 2010-09-16 | Erning Xia | Ophthalmic Compositions |
| US8846770B2 (en) * | 2008-06-18 | 2014-09-30 | Otonomy, Inc. | Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders |
| US8501800B2 (en) | 2009-03-05 | 2013-08-06 | Insite Vision Incorporated | Controlled-release ophthalmic vehicles |
| CN101966143A (zh) | 2009-07-28 | 2011-02-09 | 胡容峰 | 加替沙星温度及pH敏感眼用凝胶的制备与应用 |
| PL2965749T3 (pl) | 2009-12-03 | 2018-10-31 | Novartis Ag | Zawiesiny nanocząsteczkowe zawierające polimer karboksywinylowy |
| WO2013043387A1 (en) | 2011-09-22 | 2013-03-28 | Bausch & Lomb Incorporated | Ophthalmic gel compositions |
| KR102310775B1 (ko) | 2012-05-03 | 2021-10-07 | 칼라 파마슈티컬스, 인크. | 개선된 점막 수송을 나타내는 제약 나노입자 |
| EP3517541B1 (en) | 2012-05-08 | 2020-07-15 | Nicox Ophthalmics, Inc. | Polymorphic form of fluticasone propionate |
| US8765725B2 (en) * | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| PT2848243T (pt) | 2012-05-11 | 2023-08-02 | Activus Pharma Co Ltd | Nanopó de composto orgânico, método de produção do mesmo e suspensão |
| KR20150046300A (ko) | 2012-08-31 | 2015-04-29 | 보오슈 앤드 롬 인코포레이팃드 | 오메가-3 지방산을 함유하는 안과용 조성물 |
| US20150190407A1 (en) | 2014-01-07 | 2015-07-09 | Insite Vision Incorporated | Methods for treatment of postoperative inflammation with reduced intraocular pressure |
| NZ728131A (en) | 2014-07-11 | 2017-09-29 | Fujifilm Corp | Aqueous ophthalmic composition |
| JP6373994B2 (ja) | 2014-07-11 | 2018-08-15 | 富士フイルム株式会社 | 眼科用水性組成物の製造方法 |
| WO2016016908A1 (en) | 2014-07-28 | 2016-02-04 | Sun Pharma Advanced Research Company Limited | Method of increasing bioavailability and/or prolonging ophthalmic action of a drug |
| PT3721868T (pt) * | 2015-01-26 | 2022-08-12 | Bausch & Lomb | Composição para suspensão oftálmica |
-
2016
- 2016-01-26 PT PT201663127T patent/PT3721868T/pt unknown
- 2016-01-26 HU HUE22175139A patent/HUE066045T2/hu unknown
- 2016-01-26 PL PL22175139.9T patent/PL4082531T3/pl unknown
- 2016-01-26 CA CA2975106A patent/CA2975106A1/en not_active Abandoned
- 2016-01-26 HU HUE16704744A patent/HUE041945T2/hu unknown
- 2016-01-26 JP JP2017558359A patent/JP2018507252A/ja active Pending
- 2016-01-26 EP EP23196938.7A patent/EP4268850B1/en active Active
- 2016-01-26 PL PL18209003T patent/PL3470059T3/pl unknown
- 2016-01-26 ES ES22175139T patent/ES2966595T3/es active Active
- 2016-01-26 PL PL20166312.7T patent/PL3721868T5/pl unknown
- 2016-01-26 HU HUE20166312A patent/HUE059639T2/hu unknown
- 2016-01-26 KR KR1020177023453A patent/KR102538370B1/ko active Active
- 2016-01-26 PL PL23196938.7T patent/PL4268850T3/pl unknown
- 2016-01-26 ES ES16704744T patent/ES2704125T3/es active Active
- 2016-01-26 AU AU2016211745A patent/AU2016211745A1/en not_active Abandoned
- 2016-01-26 ES ES23196938T patent/ES3031414T3/es active Active
- 2016-01-26 MX MX2017009699A patent/MX390671B/es unknown
- 2016-01-26 PL PL16704744T patent/PL3250185T3/pl unknown
- 2016-01-26 PT PT221751399T patent/PT4082531T/pt unknown
- 2016-01-26 WO PCT/US2016/014872 patent/WO2016123079A1/en not_active Ceased
- 2016-01-26 HU HUE23196938A patent/HUE071679T2/hu unknown
- 2016-01-26 EP EP20166312.7A patent/EP3721868B2/en active Active
- 2016-01-26 CN CN201680016825.XA patent/CN107427464B/zh active Active
- 2016-01-26 EP EP22175139.9A patent/EP4082531B1/en active Active
- 2016-01-26 ES ES20166312T patent/ES2924645T5/es active Active
- 2016-01-26 BR BR112017016016-1A patent/BR112017016016B1/pt active IP Right Grant
- 2016-01-26 ES ES18209003T patent/ES2787039T3/es active Active
- 2016-01-26 EP EP18209003.5A patent/EP3470059B1/en active Active
- 2016-01-26 HU HUE18209003A patent/HUE048564T2/hu unknown
- 2016-01-26 EP EP16704744.8A patent/EP3250185B1/en not_active Revoked
- 2016-01-26 US US15/006,525 patent/US10596107B2/en active Active
- 2016-01-26 SI SI201631905T patent/SI4268850T1/sl unknown
- 2016-01-26 PT PT231969387T patent/PT4268850T/pt unknown
-
2020
- 2020-03-23 US US16/826,366 patent/US11534395B2/en active Active
-
2021
- 2021-05-12 AU AU2021203027A patent/AU2021203027B2/en active Active
-
2022
- 2022-12-21 US US18/086,286 patent/US20230140895A1/en active Pending
-
2023
- 2023-10-12 AU AU2023248145A patent/AU2023248145B2/en active Active
-
2025
- 2025-11-24 AU AU2025271194A patent/AU2025271194A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018507252A5 (enExample) | ||
| CL2019003433A1 (es) | Composición farmacéutica oftálmica que comprende nanopartículas mucopenetrantes, cuyo núcleo comprende un agente activo farmacéutico seleccionado entre un inhibidor de receptor tirosina quinasa (rtk), o un inhibidor de la angiogénesis, y está recubierto con un polímero modificador de superficie; y uso para tratar un trastorno del ojo (divisional de solicitud cl 2956-2014). | |
| CY1124917T1 (el) | Παρασκευη στερεων συμπλοκων κυκλοδεξtρινης για παραδοση οφθαλμικου δραστικου φαρμακευτικου συστατικου | |
| RU2017146716A (ru) | Способ образования наночастиц циклоспорина а/ циклодекстрина | |
| JP2015025011A5 (enExample) | ||
| MX390671B (es) | Composicion de suspension oftalmica. | |
| JP2019526532A5 (enExample) | ||
| FI2887923T3 (fi) | Polyoksylilipidin tai polyoksylirasvahapon oftalminen formulaatio ja silmätilojen hoito | |
| EP2528602A4 (en) | FORMULAS FROM BENDAMUSTIN | |
| RU2013102030A (ru) | Композиции наноструктурированного апрепитанта, способ их получения и содержащие их фармацевтические композиции | |
| JP2014527407A5 (enExample) | ||
| RU2014129268A (ru) | Офтальмологические составы, которые содержат привитые сополимеры поливинилкапролактам-поливинилацетат-полиэтиленгликоля | |
| MX2013006816A (es) | Formulaciones farmaceuticas de azol para la administracion parenteral y metodos para preparar y usar las mismas como tratamiento de las enfermedades sensibles a los compuestos de azol. | |
| AR089962A1 (es) | Composiciones farmaceuticas oftalmicas y metodos para su elaboracion y uso | |
| JP2016507526A5 (enExample) | ||
| RU2018112239A (ru) | Фармацевтическая композиция на основе трамадола для офтальмологического применения | |
| MY187552A (en) | Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions | |
| JP2016513625A5 (enExample) | ||
| RU2014125426A (ru) | Защитное средство для роговицы и конъюнктивы или супрессивное средство при кератоконъюнктивальном нарушении | |
| PE20171246A1 (es) | Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos | |
| RU2014140885A (ru) | Фармацевтическая композиция ибупрофена и трамадола для офтальмологического применения | |
| JP2017516770A5 (enExample) | ||
| JP2019515040A5 (enExample) | ||
| JP2019530729A5 (enExample) | ||
| JP2017533228A5 (enExample) |